Quoin Pharmaceuticals

Dermatology Times covers advancements in skin cancer, atopic dermatitis treatments, psoriasis care, photodynamic therapy, and more, with expert insights and FDA approvals.

Quoin Pharmaceuticals (NASDAQ:QNRX) initiated QRX003 testing in a pediatric NS patient, expanding to international sites including Saudi Arabia and the U.K. The CEO and COO increased their QNRX investments, reflecting confidence in QRX003's potential as the first approved NS treatment. Additionally, QNRX launched a QRX003 study for PSS in New Zealand.

Quoin Pharmaceuticals reported Q3 2024 net loss of $2.3M, cash position of $10.3M, initiated QRX003 clinical study for Peeling Skin Syndrome in NZ, expanded Netherton Syndrome trials with two new UK sites, and management made significant insider share purchases.

Quoin Pharmaceuticals initiates QRX003 testing in pediatric Netherton Syndrome patient in Dublin, plans expansion to Spain, Saudi Arabia, and UK. Trials show improvement across multiple endpoints with no adverse events.

Quoin Pharmaceuticals expands Netherton Syndrome clinical studies to include two UK sites, Great Ormond Street Hospital and St. Thomas’ Hospital, recognized for NS treatment. A Principal Investigator is appointed, and a Clinical Research Organization is engaged. Additional sites in Western and Eastern Europe are being finalized.

Quoin Pharmaceuticals expands Netherton Syndrome trials to include two UK sites, Great Ormond Street Hospital and St. Thomas' Hospital, under an open IND application with the US FDA. Additional sites planned in Western and Eastern Europe aim to accelerate enrollment for QRX003, a topical lotion for treating Netherton Syndrome.

Quoin Pharmaceuticals (NASDAQ: QNRX) announced significant insider share purchases by co-founders CEO Michael Myers and COO Denise Carter, reflecting leadership confidence in the company's growth trajectory and commitment to delivering long-term shareholder value. The company focuses on developing novel treatments for rare and orphan diseases.